~~<i id='08FD6844E9'><strike id='08FD6844E9'><tt id='08FD6844E9'><pre id='08FD6844E9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：knowledge 2025-10-04 11:35:31 - browse：3486

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： STAT Virtual Event: Putting AI to the Test

focus

hotspot

leisure time

focus

Wikipedia

knowledge

AdobeVerveTherapeuticssaidMondaythatithadreceivedclearancefromtheFoodandDrugAdministrationtoconducta

WSS

Medical student insurance fails on mental health care coverage

Is there really a nursing shortage in the U.S.?

Readout LOUD podcast: possible new ALS drug, artificial wombs

UnitedHealth, Optum discontinue NaviHealth name

Results on Novartis prostate cancer therapy could expand its use

CDC advisers recommend seasonal use of Pfizer RSV shot

explore

fashion

focus

ChatGPT in medicine: STAT answers readers' burning questions

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

As demand for Covid shots wanes, Moderna seeks its next success

How Vertex's cystic fibrosis drug is changing patients' lives

Medical leaders decry Supreme Court decision on affirmative action

Why are Kaiser Permanente staff considering a strike?

Hepatitis C has a cure — but many Americans still lack access to it

CZI to create biohub to build anti

hotspot

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

STAT Summit: The economic case for universal basic health care

Thermo Fisher plant for manufacturing gene therapies to expand

Hearing on Medicare drug price negotiation gets unusually heated

Medical student insurance fails on mental health care coverage

Readout LOUD podcast: Live from the 2023 STAT Summit

leisure time

focus

Wikipedia

knowledge